Vestal Point Capital LP Buys Shares of 370,000 enGene Holdings Inc. (NASDAQ:ENGN)

Vestal Point Capital LP bought a new stake in enGene Holdings Inc. (NASDAQ:ENGN) during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund bought 370,000 shares of the company’s stock, valued at approximately $2,460,000. Vestal Point Capital LP owned 0.84% of enGene at the end of the most recent reporting period.

Several other hedge funds have also recently made changes to their positions in ENGN. Vontobel Holding Ltd. bought a new stake in shares of enGene in the fourth quarter valued at $69,000. Blue Owl Capital Holdings LP raised its stake in shares of enGene by 3.3% in the fourth quarter. Blue Owl Capital Holdings LP now owns 3,159,975 shares of the company’s stock valued at $21,014,000 after buying an additional 101,006 shares during the period. Jane Street Group LLC bought a new stake in shares of enGene in the fourth quarter valued at $93,000. Cubist Systematic Strategies LLC raised its stake in shares of enGene by 15.7% in the fourth quarter. Cubist Systematic Strategies LLC now owns 15,342 shares of the company’s stock valued at $102,000 after buying an additional 2,080 shares during the period. Finally, Corton Capital Inc. purchased a new position in shares of enGene in the fourth quarter valued at $157,000. 64.16% of the stock is currently owned by institutional investors.

enGene Price Performance

enGene stock opened at $3.45 on Monday. enGene Holdings Inc. has a 52 week low of $2.65 and a 52 week high of $13.28. The business has a 50-day simple moving average of $4.18 and a 200 day simple moving average of $6.06. The company has a quick ratio of 16.87, a current ratio of 16.87 and a debt-to-equity ratio of 0.08. The stock has a market cap of $175.87 million, a price-to-earnings ratio of -5.95 and a beta of -0.36.

Wall Street Analyst Weigh In

Several brokerages have recently weighed in on ENGN. JMP Securities reiterated a “market outperform” rating and issued a $18.00 price target on shares of enGene in a research report on Tuesday, April 29th. UBS Group cut enGene from a “buy” rating to a “neutral” rating and reduced their price target for the company from $34.00 to $7.00 in a research report on Friday, February 14th. Piper Sandler began coverage on enGene in a research report on Tuesday, February 18th. They issued an “overweight” rating and a $26.00 price target for the company. Morgan Stanley reduced their price target on enGene from $37.00 to $34.00 and set an “overweight” rating for the company in a research report on Tuesday, March 11th. Finally, HC Wainwright reiterated a “buy” rating and issued a $25.00 price target on shares of enGene in a research report on Tuesday, March 11th. One investment analyst has rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, enGene presently has an average rating of “Buy” and an average target price of $23.29.

About enGene

enGene Holdings Inc, through its subsidiary enGene, Inc, operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin.